Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio (GOSS)
NASDAQ:GOSS
GOSS Stock Chart & Stats
$0.47
-$0.10(-9.01%)
At close: 4:00 PM EST
$0.47
-$0.10(-9.01%)
Day’s Range― - ―
52-Week Range$0.33 - $3.87
Previous CloseN/A
Volume602.63K
Average Volume (3M)20.89M
Market Cap
$108.78M
Enterprise Value$328.19M
Total Cash (Recent Filing)$180.22M
Total Debt (Recent Filing)$202.88M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Mar 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding231,456,250
10 Day Avg. Volume52,093,513
30 Day Avg. Volume20,885,668
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.94
Price to Sales (P/S)1.78
P/FCF Ratio-59.01
Enterprise Value/Market Cap3.02
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit7.45
Enterprise Value/Ebitda-2.25
Forecast
1Y Price Target
$4.63Price Target Upside885.11% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$43.23M
Bulls Say, Bears Say
Bulls Say
Durability And Reverse RemodelingOpen‑label extension data showed continued improvement over time, supporting a potential disease‑modifying effect on lung and right‑heart structure rather than only short‑term symptom relief.
Efficacy In High-risk SubgroupAnalysts highlight that a predefined higher‑risk patient subgroup showed clinically meaningful improvement with seralutinib, indicating the drug may deliver clear benefit for selected, more severe patients.
Mechanistic DifferentiationSeralutinib's purposeful design to target vascular remodeling, inflammation, and fibrosis offers a differentiated therapeutic rationale that could justify a stronger long‑term valuation if clinical signals persist.
Bears Say
Missed Primary EndpointPhase 3 PROSERA missed its primary endpoint because the placebo group performed better than expected, creating significant uncertainty about the strength of the treatment effect.
Placebo Variability And Durability ConcernsHigh placebo variability and attrition in the open‑label extension limit confidence in the consistency and long‑term durability of observed benefits, complicating result interpretation.
Regulatory Uncertainty And Enrollment PauseRegulatory approval path is uncertain and a related study's enrollment was paused to evaluate PROSERA results and plan regulator discussions, increasing near‑term development and regulatory risk.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was $0.33 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is $108.78M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Mar 13, 2026 which is in 8 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on Nov 05, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.19.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 231,456,250 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.63 (885.11% Upside)
$4.63 (885.11% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.49%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Stock 12 Month Forecast
Average Price Target
$4.63
▲(885.11% Upside)
Technical Analysis
Ownership Overview
3.94% Insiders
9.55% Mutual Funds
7.47% Other Institutional Investors
64.87% Public Companies and Individual Investors